These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 12615754)

  • 1. Diagnosis and management of Graves' disease.
    Ginsberg J
    CMAJ; 2003 Mar; 168(5):575-85. PubMed ID: 12615754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies.
    Cooper DS
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3474-81. PubMed ID: 12915620
    [No Abstract]   [Full Text] [Related]  

  • 4. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
    Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
    Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
    Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
    N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes of serum cytokines in hyperthyroid Graves' disease patients at diagnosis and during methimazole treatment.
    Pedro AB; Romaldini JH; Takei K
    Neuroimmunomodulation; 2011; 18(1):45-51. PubMed ID: 20628263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing Graves' ophthalmopathy.
    Wiersinga WM
    N Engl J Med; 1998 Jan; 338(2):121-2. PubMed ID: 9420345
    [No Abstract]   [Full Text] [Related]  

  • 10. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
    Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
    J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronology of Graves' ophthalmopathy in an incidence cohort.
    Bartley GB; Fatourechi V; Kadrmas EF; Jacobsen SJ; Ilstrup DM; Garrity JA; Gorman CA
    Am J Ophthalmol; 1996 Apr; 121(4):426-34. PubMed ID: 8604736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F; González-Ortiz M; Durón H; Sánchez C
    Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
    Alexander EK; Larsen PR
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthyroidism. Current treatment guidelines.
    Gittoes NJ; Franklyn JA
    Drugs; 1998 Apr; 55(4):543-53. PubMed ID: 9561343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of Yingliu mixture combined with metimazole for treating diffuse goitre with hyperthyroidism and its impact on related cytokines.
    Yang H; Cong Y; Wu T; Tang H; Ma M; Zeng J; Zhang W; Lian Z; Yang X
    Pharm Biol; 2017 Dec; 55(1):258-263. PubMed ID: 27927064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Migratory polyarthritis as an adverse effect of thiamazole use in a 13-year-old girl with Graves' disease.
    Janson JA; de Laat P; Draaisma JM
    J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1169-71. PubMed ID: 25968432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the medical treatment of Graves' hyperthyroidism.
    Marinò M; Latrofa F; Menconi F; Chiovato L; Vitti P
    J Endocrinol Invest; 2014 Nov; 37(11):1041-8. PubMed ID: 25185644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.